The important caveat: this was a Phase 2 trial
Its not a substitute for lifestyle changes
[DOI] [PMC free article] [PubMed] [Google Scholar] 96.National Institutes of Health
Across ten studies of GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP) agonists, caloric intake was reduced by approximately 1639 % compared to placebo [16]
supplemental material available online with this article
To be included, studies had to involve patients with a diagnosis of IIH according to established diagnostic (including modified Dandy or Friedman criteria) [16], administer a GLP-1 RA as an intervention, and report outcomes of interest such as ICP/CSF opening pressure, headache frequency/severity, visual function, weight/BMI, cognitive measures, and/or safety outcomes